The importance of subtype-specific KRAS mutation analysis was further highlighted in the preclinical study of Garassino et al. These authors investigated the role of different KRAS mutation subtypes (G12C, G12V, and G12D) in the in vitro chemosensitivity of human NSCLC cells and found that the expression of G12C was associated with a reduced response to cisplatin and an increased sensitivity to taxol and pemetrexed. This evidence concerns the gene KRAS and non-small cell lung carcinoma.